How to Get Wegovy or Zepbound Covered by Insurance

Most people start this process by asking their doctor. That is the right place to get a prescription, but it is the wrong place to find out whether your plan will pay for it. Coverage is decided by a document — your plan’s drug list and its written criteria — and you can read that document yourself.

This guide walks through the process in the order that actually saves time: find out what your plan says, find out which of three situations you are in, and then take the step that matches your situation. Nothing here is medical advice. Only you and a licensed healthcare provider can decide whether a GLP-1 medicine is appropriate for you. Where this guide describes how a medicine is used, it is summarizing FDA-approved labeling and Instructions for Use; follow your own prescription and your prescriber’s directions.

A note on names before we start, because plans care about them. Wegovy is semaglutide approved for chronic weight management, for reducing major cardiovascular events in adults with established heart disease plus obesity or overweight, and for MASH with moderate-to-advanced liver scarring. Zepbound is tirzepatide approved for chronic weight management and for moderate-to-severe obstructive sleep apnea in adults with obesity. Wegovy now comes in more than one form, and plans price them separately: the 1.7 mg and 2.4 mg injections, the 25 mg tablet approved in December 2025, and Wegovy HD 7.2 mg, approved March 19, 2026 for adults who have already tolerated 2.4 mg for at least four weeks [12]. Ozempic is semaglutide approved for type 2 diabetes and related uses, Mounjaro is tirzepatide approved for type 2 diabetes, and Foundayo is orforglipron, an oral GLP-1 tablet the FDA approved for chronic weight management on April 1, 2026 [13]. Plans treat each of these as a separate product with separate rules.

How do I find out if my plan covers Wegovy or Zepbound?

There are four things to check, and they take about twenty minutes.

1. Search the formulary for the exact brand name. Your plan’s formulary — also called a drug list or preferred drug list — is on your member portal and usually available as a public PDF. Search for “Wegovy” and “Zepbound” separately. Do not assume that finding one means the other is covered. On the Express Scripts 2026 National Preferred Formulary, for example, Zepbound KwikPens and Zepbound vials are excluded while Zepbound single-dose pens, Wegovy pens, Wegovy tablets, Wegovy HD, Foundayo and liraglutide are listed as preferred alternatives [3]. The device form alone can decide the answer.

2. Read the flags next to the name. Formularies use short codes. “PA” means prior authorization is required. “ST” means step therapy — you must try something else first. “QL” means a quantity limit applies. A tier number (1 through 5 on most commercial plans) tells you the copay level. Being on the formulary with a PA flag is good news; it means the category is covered and you have a process to work through.

3. Look for an exclusion in the plan documents. This is the step people skip, and it is the most important one. Open your Summary of Benefits and Coverage, the Evidence of Coverage, or the summary plan description, and search for “weight loss,” “weight management,” “anti-obesity” and “obesity.” If the plan says it does not cover drugs prescribed for weight loss, no amount of documentation will change that, because there is no benefit to appeal to. GoodRx Research reports that in 2026 roughly 7 percent of people with commercial insurance — nearly 13 million people — have no coverage for any weight-loss GLP-1 at all, and that 88 percent of those who do have coverage face restrictions [7]. That tracker blocked automated retrieval when we checked it on September 14, 2026, so treat both numbers as directional.

4. Find out whether your plan is self-funded or fully insured. In a fully insured plan, an insurance company takes the risk and state insurance law applies, so state step therapy override laws, state anti-copay-accumulator laws and state external review programs can help you. In a self-funded plan, your employer pays the claims and an insurer only administers them; federal ERISA rules apply and most state protections do not. About 67 percent of covered workers are in self-funded arrangements, rising to 80 percent at large firms [9]. Your HR department or the summary plan description will tell you which you have.

What should I ask when I call my insurance company?

Have your member ID and the exact drug name ready, and ask these in order:

• Is [Wegovy 2.4 mg / Zepbound 5 mg] on my formulary, and on which tier?
• Does my plan have an exclusion for drugs prescribed for weight loss?
• Is prior authorization required, and what is the name or number of the criteria document?
• Is step therapy required, and if so, which drugs must be tried first?
• What is the quantity limit, and does the plan allow a 90-day fill?
• Is my plan self-funded or fully insured?
• What is my remaining deductible, and what is my out-of-pocket maximum for the year?

Write down the representative’s name, the date and time, and the call reference number. If you later appeal, a contemporaneous record of what you were told matters.

Ask specifically for the criteria document. Several payers publish theirs. UnitedHealthcare posts its full weight-loss prior authorization program, including BMI thresholds, authorization durations and renewal rules, as a public PDF [1]. CVS Caremark posts standard clinical criteria for Wegovy as policy 4774-C [2]. The Blue Cross Blue Shield Federal Employee Program publishes its Zepbound policy in full [4]. Reading the criteria before your appointment means your prescriber’s first submission can answer every question the reviewer will ask.

Which of the three situations am I in?

Everything after this depends on which bucket you land in.

Situation A: covered with prior authorization. The drug is on the formulary with a PA flag and there is no weight-loss exclusion. This is the best case. Your job is to help your prescriber’s office submit a complete request the first time. Bring the criteria document to the appointment and make sure the chart contains what the plan asks for: current weight and BMI with the measurement date, a documented obesity or overweight diagnosis in the assessment (not just a code), any weight-related conditions, and a record of whatever lifestyle program or prior treatments the plan requires. UnitedHealthcare’s 2026 policy, for example, requires the drug be used as an adjunct to lifestyle modification and requires BMI at or above 30, or at or above 27 with a weight-related comorbidity such as dyslipidemia, hypertension, type 2 diabetes or sleep apnea [1].

Situation B: covered only for a different indication. Many plans that exclude weight-loss drugs still cover the same molecules for other approved uses. That is why payers maintain separate criteria sets — UnitedHealthcare’s weight-loss policy points to separate “Nonformulary Wegovy” and “Nonformulary Zepbound” criteria for plans that do not cover weight-loss medications [1]. This is a description of how policy is structured, not a suggestion to seek a diagnosis you do not have. Whether another indication applies to you is a clinical question for your provider, and in programs like the Medicare GLP-1 Bridge prescribers attest to the facts under penalty of perjury [11].

Situation C: excluded. The plan will not cover the category. Appeals against an exclusion rarely succeed. In February 2026 a federal appeals court upheld a plan’s weight-loss drug exclusion against a discrimination claim, and no federal court has held that such exclusions are unlawful. Your realistic options are a formulary exception if your plan offers one for excluded drugs — the BCBS Federal Employee Program allows this, though it explicitly will not lower your tier [4] — manufacturer self-pay pricing, an employer-sponsored direct purchase program if your company offers one, or a plan change at open enrollment.

How do I help my prescriber submit a strong prior authorization?

You are not writing the request; your prescriber is. But you can make sure nothing is missing, which is the difference between a decision in days and a month of back-and-forth.

Bring to the visit: your plan’s criteria document, your insurance card, the name of your pharmacy benefit manager, and a written weight history if you have one. Ask the office to submit electronically rather than by fax where possible, and to attach chart notes, weight history and any labs with the first submission rather than waiting for the plan to request them.

Then ask two follow-up questions. First, what is the submission date and reference number? Second, what is the plan’s decision deadline? Federal rules require urgent-care claims to be decided as soon as possible and no later than 72 hours [5]. The broader CMS Interoperability and Prior Authorization rule sets a 7-calendar-day standard and 72-hour expedited clock for Medicare Advantage, Medicaid, CHIP and Marketplace plans starting in 2026 — but that rule explicitly excludes drugs covered under the pharmacy benefit, which is where almost every GLP-1 request lives [10]. In practice, a pharmacy-benefit GLP-1 request is governed by your plan’s own contractual turnaround, so ask what it is.

What if I get approved and the copay is still high?

Approval and affordability are two different problems, and clearing one does not clear the other.

Your cost depends on four things: how much of your deductible is left, whether your plan charges a flat copay or a percentage coinsurance, how far you are from your out-of-pocket maximum, and whether a manufacturer savings card applies. On a plan with a deductible, early-year fills are typically billed at the full negotiated price until the deductible is met. A savings card can help, but each has caps — and if your plan runs a copay accumulator or maximizer, none of that manufacturer money counts toward your deductible.

There is also a tier question that is separate from the coverage question. If your drug is covered but on a high tier, some plans let you request a tiering exception; others do not. The BCBS Federal Employee Program is explicit that even when a GLP-1 is approved through a formulary exception, a tier exception cannot be requested [4].

What if I am denied?

Read the letter before you do anything else. Federal claims rules require an adverse benefit determination to state the specific reason, reference the specific plan provision relied on, describe what additional information would perfect the claim, tell you that you can request relevant documents free of charge, describe the plan’s review procedures and deadlines, and state your right to bring a civil action under ERISA [5]. If the denial rests on medical necessity, the notice must also explain the clinical judgment applied to your circumstances, or offer that explanation free on request.

Two sentences in that letter matter most. The first tells you whether this is an exclusion or a criteria denial. The second tells you your appeal deadline. Then request, in writing, a free copy of the criteria the plan applied and your complete claim file.

From there, you generally have one or two levels of internal appeal, and then the right to an independent external review whose decision the insurer must accept. You have four months from the final internal denial to request external review, standard reviews are decided within 45 days and expedited reviews within 72 hours [6]. Our companion guide walks through that process in detail.

What should I do at open enrollment?

If you are shopping plans, compare five things for each option: whether the exact drug is on the formulary, which tier it sits on, what the prior authorization criteria require, the deductible, and the out-of-pocket maximum. A plan with a lower premium and a $3,000 deductible can cost far more over a year than a plan with a higher premium and a $500 deductible if you are filling a GLP-1 every month. (Those two deductibles are illustrative round numbers, not quoted plan figures or drug prices — use the deductible printed in your own Summary of Benefits and Coverage. For context on what a year of cash-paying actually costs, Novo publishes a self-pay Wegovy pen price of $349 a month and Lilly publishes Zepbound self-pay from $299 a month, both verified 2026-09-14.)

Be realistic about what switching can achieve. Among employer plans, KFF found that 43 percent of firms with 5,000 or more workers covered GLP-1s for weight loss in 2025, falling to 30 percent of firms with 1,000 to 4,999 workers and 16 percent of firms with 200 to 999 workers [9]. On the ACA Marketplace the picture is tighter: for 2026, only 26 of 300 carriers cover GLP-1s for obesity, concentrated in nine states — California, North Dakota, New York, Vermont, Pennsylvania, West Virginia, Rhode Island, Delaware and Georgia — and all but four of those carriers require a BMI of 40 or higher [8].

And ask one question your HR team can actually answer: does the company offer a direct purchase or lifestyle account program for obesity medicines outside the pharmacy benefit? A growing number do, and those programs are often invisible on the formulary.

The short version

Read the formulary. Read the plan documents for an exclusion. Find out if you are self-funded. Get the criteria document before your appointment. Make the first submission complete. Read the denial letter for the two sentences that matter. Then use every appeal level you have — because denials are rarely appealed, and appeals often work.

Sources

1. UnitedHealthcare, Prior Authorization/Notification — Plans with Weight Loss/Appetite Suppression Medication Coverage (Program 2026 P 1114-22), effective September 1, 2026. https://www.uhcprovider.com/content/dam/provider/docs/public/prior-auth/drugs-pharmacy/commercial/r-z/PA-Notification-Weight-Loss.pdf
2. CVS Caremark, Initial Prior Authorization with Quantity Limit — Wegovy (policy 4774-C), revised August 25, 2026. https://info.caremark.com/content/dam/enterprise/caremark/microsites/dig/pdfs/pa-cf/cf_rxcriteria/CF_RxCriteria_WEGOVY_4774-C.pdf
3. Express Scripts, 2026 National Preferred Formulary Exclusions. https://www.express-scripts.com/art/open_enrollment/DrugListExclusionsAndAlternatives.pdf
4. Blue Cross Blue Shield Federal Employee Program, FAQ — Pharmacy. https://www.fepblue.org/faqs/faq-pharmacy
5. 29 CFR 2560.503-1, Claims procedure, Cornell Legal Information Institute. https://www.law.cornell.edu/cfr/text/29/2560.503-1
6. HealthCare.gov, External Review. https://www.healthcare.gov/appeal-insurance-company-decision/external-review
7. GoodRx Research, Tracking insurance coverage for weight-loss medications, 2026. https://www.goodrx.com/healthcare-access/research/tracking-insurance-coverage-weight-loss-meds
8. Leverage|Axiaci, Obesity Drug Marketplace Coverage Shrinks as Barriers Expand. https://axiacione.com/in-the-news/obesity-drug-marketplace-coverage-shrinks-as-barriers-expand
9. KFF, 2025 Employer Health Benefits Survey. https://www.kff.org/health-costs/2025-employer-health-benefits-survey
10. MACPAC, Prior Authorization in Medicaid, August 2024. https://www.macpac.gov/wp-content/uploads/2024/08/Prior-Authorization-in-Medicaid.pdf
11. Centers for Medicare & Medicaid Services, Medicare GLP-1 Bridge — Information for Providers. https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge/information-providers
12. Novo Nordisk, FDA approves Novo Nordisk’s new Wegovy HD injection, March 19, 2026. https://www.prnewswire.com/news-releases/fda-approves-novo-nordisks-new-wegovy-hd-injection-delivering-the-highest-weight-loss-to-date-for-a-wegovy-injection-adding-to-its-already-expansive-clinical-profile-302718982.html
13. Eli Lilly and Company, FDA approves Lilly’s Foundayo (orforglipron), April 1, 2026. https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-foundayotm-orforglipron-only-glp-1-pill